BioXcel Therapeutics (BTAI) Stock Forecast, Price Target & Predictions
BTAI Stock Forecast
BioXcel Therapeutics stock forecast is as follows: an average price target of $13.00 (represents a 1811.76% upside from BTAI’s last price of $0.68) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
BTAI Price Target
The average price target for BioXcel Therapeutics (BTAI) is $13.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $4.00. This represents a potential 1811.76% upside from BTAI's last price of $0.68.
BTAI Analyst Ratings
According to 8 Wall Street analysts, BioXcel Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for BTAI stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioXcel Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 15, 2024 | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | 244.83% | 1370.59% |
| Aug 15, 2023 | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | 0.63% | 488.24% |
| Jan 03, 2023 | - | H.C. Wainwright | $73.00 | $21.48 | 239.85% | 10635.29% |
| Nov 11, 2022 | - | Guggenheim | $25.00 | $14.82 | 68.69% | 3576.47% |
The latest BioXcel Therapeutics stock forecast, released on Apr 15, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $10.00, which represents a 244.83% increase from the stock price at the time of the forecast ($2.90), and a 1370.59% increase from BTAI last price ($0.68).
BioXcel Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $0.68 | $0.68 | $0.68 |
| Upside/Downside | -100.00% | -100.00% | 1370.59% |
In the current month, the average price target of BioXcel Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioXcel Therapeutics's last price of $0.68. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2023 | Wells Fargo | Buy | Buy | Hold |
| May 26, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Mar 21, 2023 | Piper Sandler | Buy | Buy | Hold |
| Mar 10, 2023 | Oppenheimer | - | Outperform | Initialise |
| Mar 10, 2023 | JonesTrading | - | Buy | Initialise |
| Mar 10, 2023 | Maxim Group | - | Buy | Initialise |
| Dec 01, 2022 | Goldman Sachs | - | Neutral | Upgrade |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
BioXcel Therapeutics's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave BTAI a "Buy" rating, the same as its previous rate.
BioXcel Therapeutics Financial Forecast
BioXcel Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $376.00K | - | - | $206.00K | $238.00K | $137.00K | - | - |
| Avg Forecast | $2.90M | $2.30M | $2.00M | $1.60M | $1.81M | $1.35M | $762.50K | $450.00K | $742.86K | $626.00K | $453.89K | $389.00K | $1.08M | $1.00M | $125.00K | $9.90K |
| High Forecast | $3.05M | $2.42M | $2.11M | $1.68M | $1.91M | $1.42M | $802.63K | $473.68K | $1.27M | $658.95K | $477.78K | $409.47K | $1.14M | $1.06M | $129.33K | $11.88K |
| Low Forecast | $2.62M | $2.08M | $1.80M | $1.44M | $1.63M | $1.22M | $687.97K | $406.01K | $317.46K | $564.81K | $409.52K | $350.98K | $974.28K | $906.57K | $119.71K | $7.92K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 0.51% | - | - | 0.53% | 0.22% | 0.14% | - | - |
BioXcel Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $450.00K, with a low forecast of $406.01K, and a high forecast of $473.68K. BTAI's average Quarter revenue forecast represents a 19.68% increase compared to the company's last Quarter revenue of $376.00K (Dec 23).
BioXcel Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-19.88M | - | - | $-49.43M | $-51.89M | $-38.99M | $-31.39M | $-26.30M |
| Avg Forecast | $580.00K | $460.00K | $400.00K | $320.00K | $362.32K | $269.72K | $152.50K | $90.00K | $148.57K | $125.20K | $90.78K | $77.80K | $215.96K | $200.96K | $-32.21M | $-22.39M |
| High Forecast | $610.53K | $484.21K | $421.05K | $336.84K | $381.39K | $283.91K | $160.53K | $94.74K | $253.97K | $131.79K | $95.56K | $81.89K | $227.33K | $211.53K | $-25.77M | $-17.91M |
| Low Forecast | $523.31K | $415.04K | $360.90K | $288.72K | $326.91K | $243.35K | $137.59K | $81.20K | $63.49K | $112.96K | $81.90K | $70.19K | $194.85K | $181.31K | $-38.65M | $-26.86M |
| Surprise % | - | - | - | - | - | - | - | - | -133.77% | - | - | -635.34% | -240.26% | -194.02% | 0.97% | 1.18% |
undefined analysts predict BTAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than BioXcel Therapeutics's previous annual EBITDA (undefined) of $NaN.
BioXcel Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-22.26M | - | - | $-51.03M | $-58.09M | $-44.62M | $-31.46M | $-26.38M |
| Avg Forecast | $-10.06M | $-12.88M | $-14.49M | $-14.09M | $-18.67M | $-18.01M | $-28.68M | $-27.17M | $-36.90M | $-51.28M | $-70.17M | $-65.15M | $-57.25M | $-52.77M | $-32.29M | $-22.45M |
| High Forecast | $-8.78M | $-11.24M | $-12.65M | $-12.30M | $-16.30M | $-16.99M | $-25.04M | $-23.72M | $-25.23M | $-44.76M | $-61.26M | $-56.88M | $-49.97M | $-46.07M | $-25.83M | $-17.96M |
| Low Forecast | $-10.75M | $-13.76M | $-15.48M | $-15.05M | $-19.95M | $-19.03M | $-30.65M | $-29.03M | $-46.31M | $-54.79M | $-74.98M | $-69.61M | $-61.16M | $-56.38M | $-38.75M | $-26.94M |
| Surprise % | - | - | - | - | - | - | - | - | 0.60% | - | - | 0.78% | 1.01% | 0.85% | 0.97% | 1.18% |
BioXcel Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BTAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioXcel Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $9.60M | - | - | $23.59M | $20.66M | $17.05M | $12.92M | $11.64M |
| Avg Forecast | $143.06M | $113.46M | $98.66M | $78.93M | $89.37M | $66.53M | $37.61M | $22.20M | $36.65M | $30.88M | $22.39M | $19.19M | $53.27M | $49.57M | $6.17M | $488.57K |
| High Forecast | $150.59M | $119.43M | $103.85M | $83.08M | $94.07M | $70.03M | $39.59M | $23.37M | $62.64M | $32.51M | $23.57M | $20.20M | $56.07M | $52.18M | $6.38M | $586.25K |
| Low Forecast | $129.08M | $102.37M | $89.02M | $71.21M | $80.63M | $60.02M | $33.94M | $20.03M | $15.66M | $27.86M | $20.20M | $17.31M | $48.06M | $44.72M | $5.91M | $390.85K |
| Surprise % | - | - | - | - | - | - | - | - | 0.26% | - | - | 1.23% | 0.39% | 0.34% | 2.10% | 23.82% |
BioXcel Therapeutics's average Quarter SG&A projection for Mar 24 is $22.20M, based on 4 Wall Street analysts, with a range of $20.03M to $23.37M. The forecast indicates a 131.17% rise compared to BTAI last annual SG&A of $9.60M (Dec 23).
BioXcel Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Mar 22 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 8 | 10 |
| EPS | - | - | - | - | - | - | - | - | $-0.76 | - | - | $-1.78 | $-2.07 | $-1.59 | $-1.12 | $-1.08 |
| Avg Forecast | $-0.25 | $-0.32 | $-0.36 | $-0.35 | $-0.46 | $-0.45 | $-0.71 | $-0.67 | $-0.92 | $-1.27 | $-1.74 | $-1.62 | $-1.42 | $-1.31 | $-1.10 | $-0.95 |
| High Forecast | $-0.22 | $-0.28 | $-0.31 | $-0.31 | $-0.40 | $-0.42 | $-0.62 | $-0.59 | $-0.63 | $-1.11 | $-1.52 | $-1.41 | $-1.24 | $-1.14 | $-1.04 | $-0.90 |
| Low Forecast | $-0.27 | $-0.34 | $-0.38 | $-0.37 | $-0.50 | $-0.47 | $-0.76 | $-0.72 | $-1.15 | $-1.36 | $-1.86 | $-1.73 | $-1.52 | $-1.40 | $-1.15 | $-1.00 |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | - | - | 1.10% | 1.46% | 1.21% | 1.02% | 1.13% |
According to undefined Wall Street analysts, BioXcel Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BTAI previous annual EPS of $NaN (undefined).
BioXcel Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| BTAI | BioXcel Therapeutics | $0.68 | $13.00 | 1811.76% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| TGTX | TG Therapeutics | $23.73 | $26.40 | 11.25% | Buy |
| EXEL | Exelixis | $26.46 | $28.00 | 5.82% | Buy |
BTAI Forecast FAQ
Is BioXcel Therapeutics a good buy?
Yes, according to 8 Wall Street analysts, BioXcel Therapeutics (BTAI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of BTAI's total ratings.
What is BTAI's price target?
BioXcel Therapeutics (BTAI) average price target is $13 with a range of $4 to $25, implying a 1811.76% from its last price of $0.68. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioXcel Therapeutics stock go up soon?
According to Wall Street analysts' prediction for BTAI stock, the company can go up by 1811.76% (from the last price of $0.68 to the average price target of $13), up by 3576.47% based on the highest stock price target, and up by 488.24% based on the lowest stock price target.
Can BioXcel Therapeutics stock reach $1?
BTAI's average twelve months analyst stock price target of $13 supports the claim that BioXcel Therapeutics can reach $1 in the near future.
What are BioXcel Therapeutics's analysts' financial forecasts?
BioXcel Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.37M (high $4.6M, low $3.95M), average EBITDA is $874.54K (high $920.57K, low $789.06K), average net income is $-92.537M (high $-82.047M, low $-98.656M), average SG&A $215.71M (high $227.06M, low $194.63M), and average EPS is $-2.299 (high $-2.038, low $-2.451). BTAI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $8.8M (high $9.26M, low $7.94M), average EBITDA is $1.76M (high $1.85M, low $1.59M), average net income is $-51.524M (high $-44.977M, low $-55.049M), average SG&A $434.11M (high $456.96M, low $391.68M), and average EPS is $-1.28 (high $-1.117, low $-1.368).
Did the BTAI's actual financial results beat the analysts' financial forecasts?
Based on BioXcel Therapeutics's last annual report (Dec 2023), the company's revenue was $1.38M, which missed the average analysts forecast of $2.21M by -37.61%. Apple's EBITDA was $-168M, missing the average prediction of $442.35K by -37993.19%. The company's net income was $-179M, missing the average estimation of $-224M by -19.89%. Apple's SG&A was $83.41M, missing the average forecast of $109.11M by -23.55%. Lastly, the company's EPS was $-6.15, beating the average prediction of $-5.553 by 10.76%. In terms of the last quarterly report (Dec 2023), BioXcel Therapeutics's revenue was $376K, missing the average analysts' forecast of $742.86K by -49.38%. The company's EBITDA was $-19.875M, missing the average prediction of $148.57K by -13477.44%. BioXcel Therapeutics's net income was $-22.256M, missing the average estimation of $-36.899M by -39.68%. The company's SG&A was $9.6M, missing the average forecast of $36.65M by -73.80%. Lastly, the company's EPS was $-0.76, missing the average prediction of $-0.917 by -17.09%